NCT00339196View on ClinicalTrials.gov

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Acute Myelogenous Leukaemia (AML)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

5 azacytidine - VALPROIC acid- Retinoic acid

5 azacytidine - VALPROIC acid- Retinoic acid

Trial Locations (1)

75010

Chu Saint Louis, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00339196 - 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | Biotech Hunter | Biotech Hunter